Pharmacognosy intro
Santalum album L., family Santalaceae, is a hemiparasitic evergreen tree whose essential oil is steam-distilled from heartwood and roots of mature specimens (minimum 15-30 years old). Known as sandalwood, chandan (Hindi/Sanskrit), tan xiang (Chinese), and byakudan (Japanese), S. album is listed as IUCN Vulnerable due to severe depletion of wild populations. Australian sandalwood (S. spicatum) and Hawaiian sandalwood (S. paniculatum) serve as sustainable alternatives with similar but not identical chemistry. Quality is defined by ISO 3518, requiring a minimum of 90% total santalols. The oil contains over 230 identified constituents, dominated by two sesquiterpene alcohols. (Z)-alpha-Santalol (41-55%) is the primary bioactive compound, functioning as a COX-2 and PGE2 suppressor in inflammatory pathways, a skin cancer chemopreventive agent (inducing cell cycle arrest and apoptosis in tumor cells while sparing normal keratinocytes), an anxiolytic, and an antimicrobial. (Z)-beta-Santalol (16-24%) provides complementary anti-inflammatory, antimicrobial, and cytotoxic activity against melanoma and breast cancer cell lines. (E,E)-Farnesol, an acyclic sesquiterpene alcohol, disrupts bacterial quorum sensing. Alpha-santalal contributes warm, milky aromatic facets and additional antimicrobial activity. Sharma et al. (2013, Phytotherapy Research) demonstrated the molecular mechanism underlying sandalwood's millennia-old use for inflammatory skin conditions: alpha-santalol suppresses PGE2 and TXB2 production in human skin cells via COX-2 inhibition. Santha and Dwivedi (2013, Photochemistry and Photobiology) established alpha-santalol as a promising topical chemopreventive agent, showing that it prevents UVB-induced skin carcinogenesis through cell cycle arrest and apoptosis in tumor cells while leaving normal keratinocytes unaffected. A series of studies by Satou et al. (2013, 2015) demonstrated anxiolytic and sedative behavioral effects from sandalwood oil inhalation in animal models, with the mechanism involving modulation of GABAergic and serotonergic neurotransmission. Human clinical evidence for anxiolytic effects remains primarily observational and traditional rather than large-scale RCT-confirmed, though the preclinical mechanistic data is robust. Toxicity is low: LD50 exceeds 5.00 g/kg (oral, rat), classified as not toxic. No significant drug interactions are documented at aromatherapy doses. Skin sensitivity is possible but rare.